Clinical trials for Romidepsin plus Flavopiridol could advance clinic research in mesothelioma treatments.
A Phase 1 study is currently underway to determine if the cancer treatment drug Romidepsin when combined with the drug Flavopiridol have a detrimental effect on cancer cells in patients with
malignant pleural mesothelioma, advanced primary lung or esophageal cancer, or lung or pleural metastases. These clinical trials on Flavopiridol and Romidepsin are being conducted at The National Institute of Health Center in Bethesda, Maryland, by principal investigators Dr. Dao Nguyen and Dr. David Schrump.
As an anticancer agent, Romidepsin is apart of a class of drugs known as histone deacetylase inhibitors. These cancer treatment drugs work by manipulating the genes in cancer cells that regulate cell growth, in effect, prompting in them apoptosis-cell death. When used by itself, the anticancer properties of Romidepsin are frustrated by a protein product generated by it called p21, which limits the drug's ability to cause apoptosis.
In these clinical trials, by administering Flavopiridol along with Romidepsin, researchers are hopeful that patients will have a reduction in p21 thus allowing the anticancer properties of Romidepsin to have a greater effect.
This phase 1 clinical trial of Romidepsin with Flavopiridol will study the safety and success rate of this regimen of cancer treatment drugs on patients.
For further information on
clinical research, mesothelioma treatment with Romidepsin and Flavopiridol, please click on the link shown to access the website of the National Cancer Institute.
Mesothelioma cancer treatment drugs are a necessity in the fight against this disease caused by Asbestos exposure. At this time, Asbestos is the only known
cause of mesothelioma, a virulent form of cancer that occurs mainly in the lining of the lungs and stomach. Asbestos can also cause lung cancer, Asbestosis, and other malignant diseases.
